To test whether d-mannose powder is effective for recurrent urinary tract infection (UTI) prevention.
Materials and methods
After initial antibiotic treatment of acute cystitis, 308 women with history of recurrent UTI and no other significant comorbidities were randomly allocated to three groups. The first group (n = 103) received prophylaxis with 2 g of d-mannose powder in 200 ml of water daily for 6 months, the second (n = 103) received 50 mg Nitrofurantoin daily, and the third (n = 102) did not receive prophylaxis.
Overall 98 patients (31.8 %) had recurrent UTI: 15 (14.6) in the d-mannose group, 21 (20.4) in Nitrofurantoin group, and 62 (60.8) in no prophylaxis group, with the rate significantly higher in no prophylaxis group compared to active groups (P < 0.001). Patients in d-mannose group and Nitrofurantoin group had a significantly lower risk of recurrent UTI episode during prophylactic therapy compared to patients in no prophylaxis group (RR 0.239 and 0.335, P < 0.0001). In active groups, 17.9 % of patients reported side effects but they were mild and did not require stopping the prophylaxis. Patients in d-mannose group had a significantly lower risk of side effects compared to patients in Nitrofurantoin group (RR 0.276, P < 0.0001), but the clinical importance of this finding is low because Nitrofurantoin was well tolerated.
In our study, d-mannose powder had significantly reduced the risk of recurrent UTI which was no different than in Nitrofurantoin group. More studies will be needed to validate the results of this study, but initial findings show that d-mannose may be useful for UTI prevention.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Foxman B, Brown P (2003) Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am 17:227–241
Ikäheimo R, Siitonen A, Heiskanen T, Kärkkäinen U, Kuosmanen P, Lipponen P, Mäkelä PH (1996) Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis 22:91–99
Griebling TL (2005) Urologic diseases in America project: trends in resource use for urinary tract infections in women. J Urol 173:1281–1287
Nickel JC (2005) Practical management of recurrent urinary tract infections in premenopausal women. Rev Urol 7:11–17
Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C (2004) Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 3:CD001209
Gupta K, Stamm WE (1999) Pathogenesis and management of recurrent urinary tract infecitons in women. World J Urol 17:415–420
Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A (2009) The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 34:407–413
Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Palatnik LP, Johnson J, Noreddin A, Harding GK, Nicolle LE, Hoban DJ (2005) Antibiotic resistance in outpatient urinary isolates: final results from the North American urinary tract infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 26:380–388
Schaeffer AJ, Amundsen SK, Jones JM (1980) Effect of carbohydrates on adherence of Escherichia coli to human urinary tract epithelial cells. Infect Immun 30:531–537
Schaeffer AJ, Chmiel JS, Duncan JL, Falkowski WS (1984) Mannose-sensitive adherence of Escherichia coli to epithelial cells from women with recurrent urinary tract infections. J Urol 131:906–910
Bouckaert J, Berglund J, Schembri M, De Genst E, Cools L, Wuhrer M, Hung CS, Pinkner J, Slättegård R, Zavialov A, Choudhury D, Langermann S, Hultgren SJ, Wyns L, Klemm P, Oscarson S, Knight SD, De Greve H (2005) Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol 55:441–455
Michaels EK, Chmiel JS, Plotkin BJ, Schaeffer AJ (1983) Effect of d-mannose and d-glucose on Escherichia coli bacteriuria in rats. Urol Res 11:97–102
Gouin SG, Wellens A, Bouckaert J, Kovensky J (2009) Synthetic multimeric heptyl mannosides as potent antiadhesives of uropathogenic Escherichia coli. Chem Med Chem 4:749–755
Barbosa-Cesnik C, Brown MB, Buxton M, Zhang L, DeBusscher J, Foxman B (2011) Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial. Clin Infect Dis 52:23–30
Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M (2001) Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 322:1571
Semins MJ, Shore AD, Makary MA, Weiner J, Matlaga BR (2012) The impact of obesity on urinary tract infection risk. Urology 79:266–269
Saliba W, Barnett-Griness O, Rennert G (2012) The association between obesity and urinary tract infection. Eur J Intern Med 24:127–131
Milo G, Katchman EA, Paul M, Christiaens T, Baerheim A, Leibovici L (2005) Duration of antibacterial treatment for uncomplicated urinary tract infection in women. Cochrane Database Syst Rev 18:CD004682
Schmiemann G, Gágyor I, Hummers-Pradier E, Bleidorn J (2012) Resistance profiles of urinary tract infections in general practice—an observational study. BMC Urol 12:33
Brumfitt W, Hamilton-Miller JM (1998) Efficacy and safety profile of long-term nitrofurantoin in urinary infections: 18 years’ experience. J Antimicrob Chemother 42:363–371
Guay DR (2009) Cranberry and urinary tract infections. Drugs 69:775–807
Gupta K, Chou MY, Howell A, Wobbe C, Grady R, Stapleton AE (2007) Cranberry products inhibit adherence of p-fimbriated Escherichia coli to primary cultured bladder and vaginal epithelial cells. J Urol 177:2357–2360
Jepson RG, Williams G, Craig JC (2012) Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 10:CD001321
Conflict of interest
All authors state that they have no conflict of interest.
About this article
Cite this article
Kranjčec, B., Papeš, D. & Altarac, S. d-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol 32, 79–84 (2014). https://doi.org/10.1007/s00345-013-1091-6
- Urinary tract infection